Editor’s Picks: The Best of 2009 From Xconomy Seattle

Every day in 2009, I got out of bed and thought about how to create excellent, original stories for Xconomy Seattle. So did my brother-in-arms, editor Greg Huang.

We want Xconomy to be a source of original, in-depth, engaging content for you. We are always looking to dig up things about the local tech, biotech, and cleantech communities that you won’t find anywhere else. We know Xconomy is not your only source of news and information, but we want it to be your favorite source, on all kinds of innovation happening here in the Northwest. Every day of the work week.

So while Greg and I certainly do keep score on our unique visitors and page views, and we are proud of the growth in readership, that’s not what we think will set us apart over time. We will keep looking for excellent stories; unique stories; ones like the editor’s picks that I’m listing below. We hope you enjoy them, and maybe you’ll even turn us on to a few more exciting ideas and entrepreneurs in 2010.

The top seven technology stories:

The Rise of Seattle’s High-Tech Cluster, As Told by Madrona’s Tom Alberg

From MIT Blackjack Team to Amazon Acquisition: The Lexcycle Story

Royalty Based Venture Financing, Born in Boston, Could Shake Up VCs and Startups from New England to the Northwest

A Tale of Three Cities: How Boston, Boulder, and Seattle Measure Up as Tech Innovation Hubs

Cray’s Comeback: CEO Peter Ungaro on Clouds, Exaflops, and the Future of Supercomputing

New Microsoft Board Member Maria Klawe on Bill Gates, College Students, & Seattle Innovation

Data Domain Founder, Kai Li, on EMC Acquisition and the Future of Data Storage

UW Computer Scientist Oren Etzioni on Startups, Venture Capital, and the Future of Web Search

The top seven biotech stories:

Dendreon Saga Heads Toward Climax as Cancer Drug Aims to Prove It Prolongs Lives

Born a Creationist, Merck’s Schadt Leads Open Source Effort to Unravel Genome

UW’s Protein Guru, David Baker, Eyes Alternative Biofuels, Vaccines in New 3-D Structures

Cell Therapeutics Teeters on the Brink as Cash Runs Out on Promising Cancer Drugs

Vertex Drug Could be ‘Man on the Moon’ for Cystic Fibrosis, Says UW Researcher Bonnie Ramsey

Clarisonic Skin Cleanser Cracks $40M in Sales on Kudos from Oprah and YouTube Beauty Queen

PATH, Fueled by Bill Gates’ Fortune, Builds Global Health Hothouse in Seattle

The top four cleantech stories:

Will Solar Ever Live Up to the Hype? Paul Allen, Vinod Khosla Bet on Infinia’s Sun Engines

The Washington Cleantech Cluster: The A-to-Z List of Alternative Energy Players

With Cash From Siemens and ArcelorMittal, Powerit Looks to Expand, Tap the Smart Grid

Green Car Company Rides Wave of Plug-In Hybrids, Battery Technology

Author: Luke Timmerman

Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.